Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis

Seminars in Arthritis and Rheumatism

Volumn 44, Issue 4, 2015, Pages 428-436

  Bosello, Silvia L ^a   De Luca, Giacomo ^a   Rucco, Manuela ^a   Berardi, Giorgia ^a   Falcione, Matteo ^b   Danza, Francesco Maria ^b   Pirronti, Tommaso ^b   Ferraccioli, Gianfranco ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b Istituto di Radiologia di Universita Cattolica del Sacro Cuore di Roma   (Italy)

Author keywords

B cells; CD20 depletion therapy; Lung involvement; Skin fibrosis; Systemic sclerosis

Indexed keywords

METHYLPREDNISOLONE; RITUXIMAB; CD20 ANTIGEN; CYCLOPHOSPHAMIDE; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; FORCED VITAL CAPACITY; HUMAN; LONG TERM CARE; LUNG DIFFUSION CAPACITY; LUNG DISEASE; MALE; PRIORITY JOURNAL; SYSTEMIC SCLEROSIS; TOTAL LUNG CAPACITY; B LYMPHOCYTE; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFECTS; IMMUNOLOGY; LUNG; LUNG FUNCTION TEST; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; RADIOGRAPHY; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; SKIN; TIME; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; B-LYMPHOCYTES; CYCLOPHOSPHAMIDE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG; MALE; MIDDLE AGED; RESPIRATORY FUNCTION TESTS; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; SKIN; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84926341813     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2014.09.002     Document Type: Article

References (49)

1. Medsger T.A., Masi A.T. Epidemiology of progressive systemic sclerosis. Clin Rheum Dis 1979, 5:15-25.
2. Lally E.V., Jimenez S.A., Kaplan S.R. Progressive systemic sclerosis: mode of presentation, rapidly progressive disease course, and mortality based on an analysis of 91 patients. Semin Arthritis Rheum 1988, 18:1-13.
3. Pope J.E., Bellamy N., Seibold J.R., Baron M., Ellman M., Carette S., et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001, 44:1251-1358.
4. van den Hoogen F.H., Boerbooms A.M., Swaak A.J., Rasker J.J., van Lier H.J., van de Putte LB. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol 1996, 35:364-372.
5. Hoyles R.K., Ellis R.W., Wellsbury J., Lees B., Newlands P., Goh N.S., et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006, 54:3962-3970.
6. Tashkin D.P., Elashoff R., Clements P.J., Goldin J., Roth M.D., Furst D.E., et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006, 354:2655-2666.
7. Mouthon L., Berezne A., Guillevin L., Valeyre D. Therapeutic options for systemic sclerosis related interstitial lung diseases. Respir Med 2010, 104:S59-S69.
8. Smith V., van Praet J.T., Vandooren B., van der Cruyssen B., Naeyaert J.M., Decuman S., et al. Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis 2010, 69:193-197.
9. Lafyatis R., Kissin E., York M., Farina G., Viger K., Fritzler M.J., et al. B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 2009, 60:578-583.
10. Bosello S., De Santis M., Lama G., Spanò C., Angelucci C., Tolusso B., et al. B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial. Arthritis Res Ther 2010, 12:R54.
11. Daoussis D., Liossis S.N., Tsamandas A.C., Kalogeropoulou C., Paliogianni F., Sirinian C., et al. Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis. Clin Exp Rheumatol 2012, 30:S17-S22.
12. Smith V., Piette Y., Van Praet J.T., Decuman S., Deschepper E., Elewaut D., et al. Two year results of an open pilot study of 2-treatment course with rituximab in patients with early systemic sclerosis in diffuse skin involvement. J Rheumatol 2013, 40:52-57.
13. Daoussis D., Liossis S.N., Tsamandas A.C., Kalogeropoulou C., Kazantzi A., Korfiatis P., et al. Is there a role for B-cell depletion as therapy for scleroderma? A case report and review of the literature. Semin Arthritis Rheum 2010, 40:127-136.
14. McGonagle D., Tan A.L., Madden J., Rawstron A.C., Rehman A., Emery P., et al. Successful treatment of resistant scleroderma-associated interstitial lung disease with rituximab. Rheumatology 2008, 47:552-553.
15. Yoo W. Successful treatment of steroid and cyclophosphamide-resistant diffuse scleroderma-associated interstitial lung disease with rituximab. Rheumatol Int 2012, 32:795-798.
16. Fabri M., Hunzelmann N., Krieg T., Rubbert A. Discordant response to rituximab in a systemic sclerosis patient with associated myositis. J Am Acad Dermatol 2008, 58:S127-S128.
17. Daoussis D., Liossis S.N., Tsamandas A.C., Kalogeropoulou C., Kazantzi A., Sirinian C., et al. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford) 2010, 49:271-280.
18. Hasegawa M., Hamaguchi Y., Yanaba K., Bouaziz J.D., Uchida J., Fujimoto M., et al. B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. Am J Pathol 2006, 169:954-966.
19. Bosello S., De Luca G., Tolusso B., Lama G., Angelucci C., Sica G., et al. B cells in systemic sclerosis: a possible target for therapy. Autoimmun Rev 2011, 10:624-630.
20. Whitfield M.L., Finlay D.R., Murray J.I., Troyanskaya O.G., Chi J.T., Pergamenschikov A., et al. Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci U S A 2003, 100:12319-12324.
21. Lafyatis R., O'Hara C., Feghali-Bostwick C.A., Matteson E. B cell infiltration in systemic sclerosis-associated interstitial lung disease. Arthritis Rheum 2007, 56:3167-3168.
22. De Santis M., Bosello S.L., Peluso G., Pinnelli M., Alivernini S., Zizzo G., et al. Bronchoalveolar lavage fluid and progression of scleroderma interstitial lung disease. Clin Respir J 2012, 6:9-17.
23. Alfonse T. Masi Subcommittee For Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980, 23:581-590.
24. Valentini G., D'Angelo S., Della Rossa A., Bencivelli W., Bombardieri S. European scleroderma study group to define disease activity criteria for systemic sclerosis. IV: assessment of skin thickening by modified Rodnan skin score. Ann Rheum Dis 2003, 62:904-905.
25. Valentini G., Silman A.J., Veale D. Assessment of disease activity. Clin Exp Rheumatol 2003, 21:S39-S41.
26. Medsger T.A., Bombardieri S., Czirjak L., Scorza R., Della Rossa A., Bencivelli W. Assessment of disease severity and prognosis. Clin Exp Rheumatol 2003, 21:S42-S46.
27. American Thoracic Society Standardization of spirometry-1994 update. Am J Respir Crit Care Med 1995, 152:1107-1136.
28. American Thoracic Society Single breath carbon monoxide diffusing capacity (transfer factor). recommendation for a standard technique-1995 update. Am J Respir Crit Care Med 1995, 152:2185-2198.
29. Egan J.J., Martinez F.J., Wells A.U., Williams T. Lung function estimates in idiopathic pulmonary fibrosis: the potential for a simple classification. Thorax 2005, 60:270-273.
30. Behr J., Furst D.E. Pulmonary function tests. Rheumatol 2008, 47:65-67.
31. Kazerooni E.A., Martinez F.J., Flint A., Jamadar D.A., Gross B.H., Spizarny D.L., et al. Thin-section CT obtained at 10mm increments versus three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring. Am J Roentgenol 1997, 169:977-983.
32. De Santis M., Bosello S., La Torre G., Capuano A., Tolusso B., Pagliari G., et al. Functional, radiological and biological markers of alveolitis and infections of the lower respiratory tract in patients with systemic sclerosis. Respir Res 2005, 6:96.
33. De Santis M., Bosello S.L., Capoluongo E., Inzitari R., Peluso G., Lulli P., et al. A vascular endothelial growth factor deficiency characterises scleroderma lung disease. Ann Rheum Dis 2012, 71:1461-1465.
34. Kowal-Bielecka O., Landewé R., Avouac J., Chwiesko S., Miniati I., Czirjak L., et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2009, 68:620-628.
35. Walker K.M., Pope J., Scleroderma Clinical Trials Consortium, Canadian Scleroderma Research Group Expert agreement on EULAR/EUSTAR recommendations for the management of systemic sclerosis. J Rheumatol 2011, 38:1326-1328.
36. Steen V.D., Owens G.R., Fino G.J., Rodnan G.P., Medsger T.A. Pulmonary involvement in systemic sclerosis (scleroderma). Arthritis Rheum 1985, 28:759-767.
37. Fisher A., du Bois R. Interstitial lung disease in connective tissue disorders. Lancet 2012, 380:689-698.
38. Steen V.D., Conte C., Owens G.E., Medsger T.A. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994, 37:1283-1289.
39. Khanna D., Tseng C.H., Farmani N., Steen V., Furst D.E., Clements P.J., et al. Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo Group. Arthritis Rheum 2011, 63:3078-3085.
40. Keir G.J., Maher T.M., Hansell D.M., Denton C.P., Ong V.H., Singh S., et al. Severe interstitial lung disease in connective tissue disease: rituximab as a rescue therapy. Eur Respir J 2012, 40:641-648.
41. Jordan S., Distler J.H., Maurer B., Huscher D., van Laar J.M., Allanore Y., et al. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis 2014, 10.1136/annrheumdis-2013-204522.
42. Gazi H., Pope J.E., Clements P., Medsger T.A., Martin R.W., Merkel P.A., et al. Outcome measurements in scleroderma: results from a Delphi exercise. J Rheumatol 2007, 34:501-509.
43. Denton C.P., Merkel P.A., Furst D.E., Khanna D., Emery P., Hsy V.M., et al. Recombinant human anti-transforming growth factor beta 1 antibody therapy in systemic sclerosis-a multicentre, randomized, placebo-controlled phase I/II trial of CA192. Arthritis Rheum 2007, 56:323-333.
44. Burt R.K., Shah S.J., Dill K., Grant T., Gheorghiade M., Schroeder J., et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet 2011, 378:498-506.
45. Francois A., Chatelus E., Wachsmann D., Sibilia J., Bahram S., Alsaleh G., et al. B lymphocytes and B-cell activating factor promote collagen and profibrotic markers expression by dermal fibroblasts in systemic sclerosis. Arthritis Res Ther 2013, 15:R168.
46. Elhai M., Meune C., Avouac J., Kahan A., Allanore Y. Trends in mortality inpatients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford) 2012, 51:1017-1026.
47. Buch M.H., Smolen J.S., Betteridge N., Breedveld F.C., Burmester G., Dörner T., et al. Updated consensus statement on the use of RTX in patients with rheumatoid arthritis. Ann Rheum Dis 2011, 70:909-920.
48. Keystone E.C., Cohen S.B., Emery P., Kremer J.M., Dougados M., Loveless J.E., et al. Multiple courses of rituximab produce sustained clinical and radiographic efficacy and safety in patients with rheumatoid arthritis and an inadequate response to 1 or more tumor necrosis factor inhibitors: 5-year data from the REFLEX study. J Rheumatol 2012, 39:2238-2246.
49. Emery P., Mease P.J., Rubbert-Roth A., Curtis J.R., Müller-Ladner U., Gaylis N.B., et al. Retreatment with RTX based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a retrospective pooled analysis. Rheumatology 2011, 50:2223-2232.